Applied Therapeutics Inc. (NASDAQ:APLT) Receives $6.10 Average Target Price from Analysts

Applied Therapeutics Inc. (NASDAQ:APLT) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $6.10.

Separately, Wall Street Zen raised Applied Therapeutics to a “sell” rating in a research note on Saturday, July 26th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Toronto Dominion Bank bought a new position in Applied Therapeutics in the fourth quarter valued at about $27,000. CreativeOne Wealth LLC grew its position in Applied Therapeutics by 132.2% in the first quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company’s stock valued at $25,000 after acquiring an additional 28,701 shares during the last quarter. California State Teachers Retirement System grew its position in Applied Therapeutics by 923.3% in the fourth quarter. California State Teachers Retirement System now owns 71,282 shares of the company’s stock valued at $61,000 after acquiring an additional 64,316 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Applied Therapeutics in the fourth quarter valued at about $102,000. Finally, HighTower Advisors LLC bought a new position in Applied Therapeutics in the first quarter valued at about $59,000. Institutional investors own 98.31% of the company’s stock.

Applied Therapeutics Stock Up 8.2%

APLT stock opened at $0.45 on Tuesday. The company has a market cap of $64.11 million, a PE ratio of -0.99 and a beta of 2.06. The business has a 50-day simple moving average of $0.47 and a 200 day simple moving average of $0.43. Applied Therapeutics has a 52 week low of $0.30 and a 52 week high of $10.62.

Applied Therapeutics (NASDAQ:APLT) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02. On average, analysts anticipate that Applied Therapeutics will post -0.65 EPS for the current fiscal year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.